Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer
Purpose: Endocrine resistance hormone receptor-positive (HR+) advanced breast cancer (ABC) is generally insensitive to immunecheckpoint inhibitors (ICIs). This study sought to determine whether PI3Kδ inhibitor could enhance the sensitivity of endocrine resistance HR + advanced BC to ICIs by reducing...
Main Authors: | Yingjue Li, Yiwen Li, Yu Yang, Yuwei Deng, Xiangdong Ni, Bochen Zhao, Zhaoqi Yan, Wen He, Yixin Li, Shuhui Li, Linbo Liu, Dan Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-08-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023057067 |
Similar Items
-
The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
by: Jing Xu, et al.
Published: (2023-07-01) -
Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
by: Inga Bekes, et al.
Published: (2023-08-01) -
Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial
by: Jiayu Chen, et al.
Published: (2022-09-01) -
Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
by: Wenqing Jia, et al.
Published: (2022-09-01) -
Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer
by: Li Huifang, et al.
Published: (2022-12-01)